Oncomine Precision Assay receives breakthrough device designation by FDA
The assay can be used to identify low-grade glioma patients with isocitrate dehydrogenase IDH1, IDH2 mutation
Recover your password.
A password will be e-mailed to you.
- Advertisement -
Recover your password.
A password will be e-mailed to you.